Sometimes it does not feel like sadness.

It feels like distance.

Music does not land the same way. Conversations feel flatter. The things that once sparked curiosity or excitement begin to feel muted.

Other times the experience is different. The mind feels tight or restless. Small things create tension. Thoughts loop longer than they should, and it becomes harder to feel present in the moment.

Researchers often describe one part of this experience as anhedonia — a reduced ability to feel pleasure or emotional reward. But mood changes can also show up as tension, rumination, low motivation, or a sense of emotional disconnection.

gentle’s Mood Protocol is designed for those moments when you want to feel more like yourself again.

Instead of trying to mute emotions or artificially boost mood, the protocol supports the brain systems involved in reward, motivation, emotional regulation, and a steadier sense of presence.

The Protocol

The gentle Mood Protocol follows the structure commonly used in clinical tDCS research while adapting it into a sustainable weekly rhythm.

Activation Phase

Most clinical protocols rely on repeated stimulation across several weeks to build cumulative effects.

gentle follows a similar structure during the activation phase:

• 30-minute sessions
• 5 sessions per week
• 3–5 weeks of consistent practice

This phase is designed to gradually support the neural systems involved in reward processing, emotional regulation, and motivation.

Consistency matters more than intensity. The effects of stimulation appear to build through repeated exposure over time.

Maintenance Phase

After the activation phase, many people shift to a lighter rhythm to maintain the benefits.

Typical maintenance patterns include:

• 2–3 sessions per week
• sessions during periods of stress or low mood
• occasional return to an activation cycle when needed

The exact cadence varies between individuals. Some people prefer a consistent weekly routine, while others use sessions more flexibly depending on how they feel.

How frontal tDCS effects mood

Transcranial Direct Current Stimulation (tDCS) is a form of non-invasive brain stimulation that delivers a very low electrical current across electrodes placed on the scalp [1][4].

Rather than forcing the brain into a specific state, the stimulation gently biases neural excitability, making certain networks slightly more likely to activate and communicate with one another [4][14].

Many clinical studies target the prefrontal cortex, a region involved in emotional regulation, cognitive control, and reward processing [4][8].

By repeatedly stimulating these networks across days or weeks, researchers believe it may be possible to gradually influence the neural systems involved in mood, motivation, and emotional regulation [8][14][15].

Evidence from Clinical Trials

tDCS has been studied in multiple randomized controlled trials for mood disorders, including large international trials and several meta-analyses.

Across this literature, results vary between studies, but several consistent patterns appear.

• Improvements in depressive symptoms

  
  Participants receiving repeated prefrontal stimulation often experience meaningful reductions in depressive symptoms over several weeks of treatment [8][14][15].
  In pooled analyses of clinical trials, approximately 57% of participants achieved remission or meaningful clinical response after structured stimulation protocols [14][15].

  
  

• Early improvements within several weeks

  
  Structured stimulation schedules delivering sessions five times per week have reported early improvements in mood symptoms. In some trial settings, roughly 77% of participants reported improvement within the first three weeks of treatment [8][15].

  
  

• Improvements in reward sensitivity and anhedonia

  
  Depression research highlights anhedonia—a reduced ability to experience pleasure or motivation—as a central symptom cluster.
  When prefrontal networks involved in reward processing become more responsive, people may gradually experience improvements in interest, engagement, and emotional responsiveness [14][15].

  
  

• Effects on anxiety and emotional tension

  
  Mood disorders frequently involve both low mood and heightened internal tension, including rumination, worry, and stress reactivity.
  Several studies report improvements in emotional regulation and anxiety-related symptoms alongside improvements in depressive symptoms when prefrontal stimulation is repeated over time [8][15].

  
  

• Repetition matters

  
  One of the clearest patterns in the literature is that outcomes depend heavily on repeated stimulation across days and weeks rather than single sessions.

Typical research protocols deliver stimulation:

• 20–30 minutes per session
• multiple sessions per week
• across several weeks

This repeated “dose” of stimulation is believed to gradually influence the prefrontal networks involved in mood regulation and emotional control [8][9][15].

A realistic interpretation

Across meta-analyses, the average effect of active stimulation compared with sham is considered modest but meaningful, with some individuals improving substantially and others showing little change [11][12][15].

This variability is why responsible descriptions of the research emphasize probability rather than guarantees.

Why gentle recommends 30-Minute Sessions

Many influential clinical trials use 20–30 minute stimulation sessions.

For example, the SELECT-tDCS trial delivered 30-minute sessions across several weeks, combining repeated stimulation with antidepressant therapy.

Later home-based studies have also used 30-minute sessions in remote or self-administered treatment models.

Thirty minutes sits comfortably inside established safety guidelines and fits naturally into a daily routine.

Safety and Responsible Use

tDCS has been studied for more than two decades and is generally considered well tolerated when used within established safety guidelines [1][2][3].

The most commonly reported sensations are mild and temporary:

• tingling
• itching under electrodes
• temporary skin redness
• mild headache

Serious adverse events are rare when stimulation follows established parameters.

Who should avoid gentle

Do not use gentle if you:

• have an implanted electronic medical device [1][2]
• have epilepsy or a seizure history [1][2]
• have bipolar disorder or a history of mania [8][7]
• are pregnant [1][2]
• have significant neurological conditions [1][2]

These groups are typically excluded from clinical trials, which is why extra caution is recommended.

The Long-Term Vision

gentle’s goal is to translate neuromodulation research into a simple daily practice that supports emotional presence and wellbeing.

Over time, protocols can become more adaptive, learning which patterns best support each person’s mood and daily rhythms.

The aim is simple: helping you feel more like yourself.

Works Cited

[1] Antal A, Alekseichuk I, Bikson M, et al. Low intensity transcranial electric stimulation: Safety, ethical, legal regulatory and application guidelines. Clin Neurophysiol. 2017;128(9):1774–1809. DOI: 10.1016/j.clinph.2017.06.001. PubMed PMID: 28709880. (PubMed)

[2] Bikson M, Grossman P, Thomas C, et al. Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. Brain Stimul. 2016;9(5):641–661. DOI: 10.1016/j.brs.2016.06.004. PubMed PMID: 27372845. (PubMed)

[3] Poreisz C, Boros K, Antal A, Paulus W. Safety aspects of transcranial direct current stimulation concerning healthy subjects and patients. Brain Res Bull. 2007;72(4–6):208–214. DOI: 10.1016/j.brainresbull.2007.01.004. PubMed PMID: 17452283. (PubMed)

[4] Brunoni AR, Nitsche MA, Bolognini N, et al. Clinical research with transcranial direct current stimulation (tDCS): Challenges and future directions. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39(1):9–16. DOI: 10.1016/j.pnpbp.2012.05.016. PubMed PMID: 22651961. (PubMed)

[5] Boggio PS, Rigonatti SP, Ribeiro RB, et al. A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression. Int J Neuropsychopharmacol. 2008;11(2):249–254. DOI: 10.1017/S1461145707007833. PubMed PMID: 17559710. (PubMed)

[6] Loo CK, Sachdev P, Martin D, et al. A double-blind, sham-controlled trial of transcranial direct current stimulation for the treatment of depression. Int J Neuropsychopharmacol. 2010;13(1):61–69. DOI: 10.1017/S1461145709990411. PubMed PMID: 19671217. (PubMed)

[7] Loo CK, Alonzo A, Martin D, et al. Transcranial direct current stimulation for depression: 3-week, randomised, sham-controlled trial. Br J Psychiatry. 2012;200(1):52–59. DOI: 10.1192/bjp.bp.111.097634. PubMed PMID: 22215866. (PubMed)

[8] Brunoni AR, Valiengo L, Baccaro A, et al. The Sertraline vs Electrical Current Therapy for Treating Depression Clinical Study (SELECT-TDCS): results of a factorial, randomized, controlled trial. JAMA Psychiatry. 2013;70(4):383–391. DOI: 10.1001/2013.jamapsychiatry.32. PubMed PMID: 23389323. (PubMed)

[9] Woodham RD, Lewin TJ, Storch EA, et al. Fully remote, home-based, direct current stimulation therapy for major depressive disorder: a randomized, sham-controlled phase 2 trial. Nat Med. 2025. DOI: 10.1038/s41591-024-03305-y. PubMed PMID: 39433921. (PubMed)

[10] Loo CK, Husain MM, McDonald WM, et al. International randomized-controlled trial of transcranial Direct Current Stimulation in depression. Brain Stimul. 2018;11(1):125–133. DOI: 10.1016/j.brs.2017.10.011. PubMed PMID: 29111077. (PubMed)

[11] Kalu UG, Sexton CE, Loo CK, Ebmeier KP. Transcranial direct current stimulation in the treatment of major depression: a meta-analysis. Psychol Med. 2012;42(9):1791–1800. DOI: 10.1017/S0033291711003059. PubMed PMID: 22236735. (PubMed)

[12] Berlim MT, Van den Eynde F, Daskalakis ZJ. Clinical utility of transcranial direct current stimulation (tDCS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. J Psychiatr Res. 2013;47(1):1–7. DOI: 10.1016/j.jpsychires.2012.09.025. PubMed PMID: 23084964. (PubMed)

[13] Shiozawa P, Fregni F, Benseñor IM, et al. Transcranial direct current stimulation for major depression: an updated systematic review and meta-analysis. Int J Neuropsychopharmacol. 2014;17(9):1443–1452. DOI: 10.1017/S1461145714000418. PubMed PMID: 24713139. (PubMed)

[14] Brunoni AR, Moffa AH, Fregni F, et al. Transcranial direct current stimulation for acute major depressive episodes: meta-analysis of individual patient data. Br J Psychiatry. 2016;208(6):522–531. DOI: 10.1192/bjp.bp.115.164715. PubMed PMID: 27056623. (PubMed)

[15] Razza LB, Palumbo P, Moffa AH, et al. A systematic review and meta-analysis on the effects of transcranial direct current stimulation in depressive episodes. Depress Anxiety. 2020;37(7):594–608. DOI: 10.1002/da.23004. PubMed PMID: 32101631. (PubMed)

[16] Wang J, Luo H, Schülke R, et al. Transcranial direct current stimulation for depression: a systematic review and meta-analysis of randomized controlled trials (including monotherapy and combination approaches). BMC Med. 2021;19:319. DOI: 10.1186/s12916-021-02181-4. PubMed PMID: 34915885. (PubMed)

[17] Razza LB, De Smet S, Moffa A, et al. Follow-up effects of transcranial direct current stimulation (tDCS) for the major depressive episode: A systematic review and meta-analysis. Psychiatry Res. 2021;302:114024. DOI: 10.1016/j.psychres.2021.114024. PubMed PMID: 34058716. (PubMed)